Physician profile
Mary E Phillips
NPI 1609016005
$1,493.49
in general payments reported to CMS, 2019-2025
15 companies · $187 in 2025
The $187 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $337 · 2022: $596 · 2023: $338 · 2024: $34.63 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $559.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $282.31 | 2021-2025 | Spravato |
| Alkermes, INC. | $279.30 | 2021-2025 | Lybalvi, Vivitrol |
| Abbvie INC. | $183.39 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $136.01 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $100.68 | 2021-2022 | |
| Bausch Health US, LLC | $93.84 | 2021-2023 | Aplenzin |
| Neurocrine Biosciences, INC. | $83.94 | 2022-2023 | Ingrezza |
| Lundbeck LLC | $74.05 | 2021-2022 | |
| Axsome Therapeutics, INC. | $62.46 | 2022-2023 | Auvelity |
| Jazz Pharmaceuticals INC. | $60.31 | 2021-2022 | |
| Neos Therapeutics, LP | $52.26 | 2021 | |
| Livanova USA, INC. | $28.50 | 2022 | |
| Hologic Sales and Service, LLC | $21.99 | 2025 | Aptima |
| Otsuka America Pharmaceutical, INC. | $17.94 | 2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $16.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.